<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00372970</url>
  </required_header>
  <id_info>
    <org_study_id>4204</org_study_id>
    <nct_id>NCT00372970</nct_id>
  </id_info>
  <brief_title>Placebo Controlled Trial of Botulinum Toxin for Gastroparesis</brief_title>
  <official_title>Randomized Placebo-Controlled Double Blind Study of Botulinum Toxin Versus Placebo for the Treatment of Gastroparesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Temple University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is hypothesized that in some patients with gastroparesis increased pyloric tone may be a
      contributing feature. Botox relaxes the pylorus so that food can empty the stomach more
      rapidly. Lesser quality studies have shown that this treatment works in about 40% of
      patients, and relieves symptoms for up to 3 months. This study compares this treatment to
      placebo (saline) injection. After a 1 month period patients may elect to receive open label
      botox who have not received relief from their first injection. Patients symptoms and gastric
      emptying are followed for 1 year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with gastroparesis, or delayed gastric emptying, present with early satiety,
      postprandial bloating, nausea, vomiting, and abdominal pain or discomfort.1 Gastric emptying
      is a highly regulated process reflecting the integration of propulsive forces generated by
      proximal fundic tone and distal antral contractions with the resistance of the pyloric
      sphincter. Antral hypomotility as well as increased gastric outlet resistance due to pyloric
      dysfunction or pylorospasm appear to be important physiologic disturbances in
      gastroparesis.2-4 Current treatment for gastroparesis employs prokinetic agents that increase
      antral contractility and accelerate gastric emptying.5 Unfortunately, prokinetic agents have
      limited efficacy and trials of these agents have suffered from significant methodological
      flaws.6 Troublesome side effects such as cardiac arrhythmias in the case of cisapride
      (Propulsid, Janssen Pharmaceutica) and extrapyramidal symptoms and sedation in the case of
      metoclopramide (Reglan, A.H. Robins) have limited the usefulness of these agents.7
      Domperidone may be effective for treating symptoms of gastroparesis, however it is
      unavailable in the U.S.8

      Botulinum toxin (Botox, Allergan) is an inhibitor of cholinergic neuromuscular transmission
      and has been used to treat spastic disorders of both striated and smooth muscles by local
      injection into affected muscles.9 Previous published work from our institution demonstrated
      that injection of botulinum toxin into the pylorus improved gastric emptying and reduces
      symptoms in idiopathic gastroparesis.10 In our open label study, patients had a 38% reduction
      in gastroparesis symptoms when interviewed 4 weeks after injection. Seventy percent of
      patients had improved gastric emptying. No immediate or short term (within 6 months) untoward
      events occurred in our study. The beneficial effect of botulinum toxin injection was
      suggested to be through decreasing pyloric resistance; however, manometric analysis of this
      region was not performed. Our results are similar to those seen in other studies that have
      demonstrated accelerated gastric emptying in response to pyloric botulinum toxin
      injection.11-13 These studies have included groups of patients with both idiopathic and
      diabetic gastroparesis. Unfortunately, in all studies, the patient groups have been very
      small and the study design has been open label that might bias results in favor of a positive
      response. In addition, follow-up has been for only 6 months.

      Despite limited data, many gastroenterologists are now using botulinum toxin injection for
      the treatment of gastroparesis outside the context of clinical research studies. We are
      concerned that this practice may be increasing nationwide without definitive proof of
      efficacy. A randomized, placebo-controlled trial is necessary to establish the usefulness of
      pyloric botulinum toxin injection for gastroparesis. Botulinum toxin therapy is expensive and
      may not be efficacious. In addition, if efficacious, the mechanism by which botulinum toxin
      improves gastric emptying needs to be studied. This research protocol will answer several
      questions concerning this potentially useful therapy for gastroparesis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom Response as Assessed by the Gastroparesis Cardinal Symptom Index.</measure>
    <time_frame>1 month</time_frame>
    <description>Scale for GI symptoms related to gastroparesis. For this we will use the gastroparesis cardinal symptom index (GCSI).
The GCSI is based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). Scores range from 0-5 for the nine items and an asymptomatic patient would have a score of 0 with a highly symptomatic patient having a score of 45. For this study the score had to be &gt;=27. In a previous study internal consistency reliability was 0.84 for the GCSI total score and ranged from 0.83 to 0.85 for the subscale scores. Two week test retest reliability was 0.76 for the total score and ranged from 0.68 to 0.81 for subscale scores.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 U of Botox injected endoscopically into pylorus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline into pylorus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin A</intervention_name>
    <description>200 U given by injection into the pylorus.</description>
    <arm_group_label>Botulinum Toxin A</arm_group_label>
    <other_name>Botox into pylorus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>saline injection into pylorus.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline injection into pylorus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented gastroparesis by radiologic study

          -  No ulcer disease

          -  Only surgery history must be either appendectomy or cholecystectomy

          -  No prior treatment with Botox

        Exclusion Criteria:

          -  Prior botox injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank K Friedenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.temple.edu/medicine/departments_centers/clinical_departments/medicine_gastro.htm</url>
    <description>GI Section Website</description>
  </link>
  <results_reference>
    <citation>Friedenberg FK, Palit A, Parkman HP, Hanlon A, Nelson DB. Botulinum toxin A for the treatment of delayed gastric emptying. Am J Gastroenterol. 2008 Feb;103(2):416-23. Epub 2007 Dec 5.</citation>
    <PMID>18070232</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2006</study_first_submitted>
  <study_first_submitted_qc>September 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2006</study_first_posted>
  <results_first_submitted>April 16, 2015</results_first_submitted>
  <results_first_submitted_qc>May 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 9, 2015</results_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Temple University</investigator_affiliation>
    <investigator_full_name>Frank K. Friedenberg</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>gastroparesis</keyword>
  <keyword>vomiting</keyword>
  <keyword>nausea</keyword>
  <keyword>bloating</keyword>
  <keyword>dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients all recruited at Temple University Hospital from 7/1/2005 to 9/1/2007</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Botulinum Toxin</title>
          <description>Received 200U of Botox injected into pyloric sphincter endoscopically.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Received 5 cc saline injected into pyloric sphincter endoscopically.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients with documented gastroparesis</population>
      <group_list>
        <group group_id="B1">
          <title>Botulinum Toxin</title>
          <description>Received 200U of Botox injected into pyloric sphincter endoscopically.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Received 5 cc saline injected into pyloric sphincter endoscopically.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.6" spread="11.6"/>
                    <measurement group_id="B2" value="40.4" spread="13.0"/>
                    <measurement group_id="B3" value="41.1" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Symptom Response as Assessed by the Gastroparesis Cardinal Symptom Index.</title>
        <description>Scale for GI symptoms related to gastroparesis. For this we will use the gastroparesis cardinal symptom index (GCSI).
The GCSI is based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). Scores range from 0-5 for the nine items and an asymptomatic patient would have a score of 0 with a highly symptomatic patient having a score of 45. For this study the score had to be &gt;=27. In a previous study internal consistency reliability was 0.84 for the GCSI total score and ranged from 0.83 to 0.85 for the subscale scores. Two week test retest reliability was 0.76 for the total score and ranged from 0.68 to 0.81 for subscale scores.</description>
        <time_frame>1 month</time_frame>
        <population>All patients had gastroparesis and underwent EGD. Injection double blinded.</population>
        <group_list>
          <group group_id="O1">
            <title>Botox</title>
            <description>Botox injection into pylorus</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>saline Injection into pylorus</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Response as Assessed by the Gastroparesis Cardinal Symptom Index.</title>
          <description>Scale for GI symptoms related to gastroparesis. For this we will use the gastroparesis cardinal symptom index (GCSI).
The GCSI is based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). Scores range from 0-5 for the nine items and an asymptomatic patient would have a score of 0 with a highly symptomatic patient having a score of 45. For this study the score had to be &gt;=27. In a previous study internal consistency reliability was 0.84 for the GCSI total score and ranged from 0.83 to 0.85 for the subscale scores. Two week test retest reliability was 0.76 for the total score and ranged from 0.68 to 0.81 for subscale scores.</description>
          <population>All patients had gastroparesis and underwent EGD. Injection double blinded.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="9.2"/>
                    <measurement group_id="O2" value="10.1" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Botox</title>
          <description>Botox injection into pylorus</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>saline Injection into pylorus</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Non-serious adverse</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Not serious adverse event</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title vocab="other">other</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>other non-serious events</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frank Friedenberg</name_or_title>
      <organization>Temple University</organization>
      <phone>215-707-9900</phone>
      <email>frank.friedenberg@temple.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

